Transforming the lives of patients with respiratory conditions Transformational Therapies to Treat Serious Lung Infections & Pulmonary Hypertension Corporate Presentation October 2019
Forward Looking Statement This presentation is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of Beyond Air, Inc. (the “Company”) nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The Company files annual, quarterly and other reports with the Securities and Exchange Commission (the “SEC”) including its Annual Report on Form 10-K for the year ended March 31, 2019 (the “Form 10-K”) which was filed on June 28, 2019. You may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. For a more complete discussion of the risk factors affecting our business, please refer to the Form 10-K. Our public communications, including this presentation, and SEC filings, may contain statements related to future, not past, events. These forward- looking statements are based upon current beliefs and expectations of Beyond Air’s management and are subject to significant risks and uncertainties. These forward-looking statements often, but not always, may be identified by the use of words such as “believes,” “estimates,” “anticipates,” “targets,” “expects,” “plans,” “projects,” “intends,” “predicts,” “may,” “could,” “might,” “will,” “should,” “approximately,” potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward looking statements. These forward-looking statements appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the patient market size and market adoption of our products by physicians and patients, the timing and cost of clinical trials for our products or whether such trials will be conducted at all, completion and receiving favorable results of clinical trials for our products, the development and approval of the use of nitric oxide for additional indications, FDA approval of, or other regulatory action with respect to, the timing, cost or other aspects of the commercial launch of our products and the commercial launch and future sales of our products or any other future products or product candidates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated or not at all. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this presentation. 2
Risk Factors Risk Ri sks as associat ated wi with ou our bu busi siness ss in inclu lude bu but ar are no not lim limit ited to to th the fo following: Investing in our common stock involves a high degree of risk. You should consider carefully the risks described below, together with the other information § included or incorporated by reference in this Annual Report on Form 10-K. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations. We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We are a clinical-stage § company. We have no approved products and have generated no revenue to date from an approved product and may never achieve profitability. Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These are not § the only risks we face. These risks include, among others, that: We are a development-stage medical device and biopharmaceutical company and have a limited operating history on which to assess our business, have § incurred significant losses since our inception, including a net loss of $6,558,450 for the year ended March 31, 2019, and an accumulated deficit of approximately $37,644,572 as of March 31, 2019, and anticipate that we will continue to incur significant losses for the foreseeable future We are unable to predict the extent of future losses or when we will become profitable based on the sale of any product, if at all. Even if we succeed in § developing and commercializing our product candidates, we may never generate revenue to sustain profitability; We do not have an approved FDA product in the market, and we expect that we will need to raise additional funding before we can expect to become § profitable from sales of our products; We are heavily dependent upon the success of our product candidates, which are in various stages of clinical development, and we cannot provide any § assurance that the FDA or other regulatory agencies will allow us to conduct further clinical trials; We are in the process of developing our proprietary NO delivery system, and unexpected delays will adversely impact the timing of our U.S.-based clinical § trials and approvals; We might be unable to develop product candidates that will achieve commercial success in a timely and cost-effective manner, or ever; § Our competitors may develop or commercialize products faster or more successfully than us; § Because some of the target patient populations of our product candidates are small, we must be able to successfully identify patients and achieve a § significant market share to maintain profitability and growth; Our reliance on third parties to help conduct our pre-clinical studies, clinical trials and commercial scale manufacturing; § We do not have any products approved for sale by the FDA or any other regulatory agencies, and we cannot provide any assurance that any of our product § candidates will receive regulatory approval; If we are unable to obtain and maintain effective intellectual property rights for our technologies, product candidates or any future product candidates, we § may not be able to compete effectively in our markets; and Our future success depends in part upon our ability to retain our executive and scientific teams, and to attract, retain and motivate other qualified personnel. § 3
Beyond Air: Revolutionizing the Delivery of Nitric Oxide (NO) Beyond Air has developed LungFit™, a proprietary platform Nitric Oxide generator and delivery system § Beyond Air’s LungFit ™ generator and delivery system generates NO from Proprietary Nitric ambient air, eliminating the need for expensive and cumbersome cylinders Oxide Technology § Beyond Air‘s system provides significant advantages over approved NO Platform cylinder based systems currently used in hospitals around the world AND may allow for use in the home setting to treat certain respiratory conditions US Sales WW Sales Launch First 3 Indications Target Patient Population Potential* Potential* Year** Address Large Pulmonary Hypertension Markets >$300m >$600m 2020 (in-hospital) Bronchiolitis (in-hospital) >$500m >$1.2b 2022 Severe Lung Infections*** (at-home) >$1b >$2.5b 2024 Demonstrated § More than 2,100 treatments in over 85 patients across 8 studies at NO concentrations >150 parts per million (ppm) Safety Profile § No Serious Adverse Events (SAEs) related to NO therapy Experienced § Deep industry experience developing NO delivery systems Management Team § Proven experience in gaining regulatory approvals for both drugs and devices on a global basis *All figures are Company estimates for peak year sales: Global Sales Potential includes US Sales Potential ** Anticipated first launch on a global basis pending appropriate regulatory approvals *** Estimates are for our first indication only (nontuberculous mycobacteria or NTM) 4
Recommend
More recommend
